Role of soluble mediators in angiogenesis

European Journal of Cancer Part A

Volumn 32, Issue 14, 1996, Pages 2401-2412

  Bussolino, F ^a   Albini, A ^b   Camussi, G ^c   Presta, M ^g   Viglietto, G ^d   Ziehe, M ^e,f   Persico, G ^g  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

^f INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; NITRIC OXIDE; POLYPEPTIDE;

AMINO ACID SEQUENCE; ANGIOGENESIS; GENE EXPRESSION; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030513075     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00390-5     Document Type: Article

References (111)

1. 1. Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res 1992, 59, 115-165.
2. 2. Gualandris A, Urbinati C, Rusnati M, Ziche M, Presta M. Interaction of high molecular weight basic fibroblast growth factor (bFGF) with endothelium: biological activity and intracellular fate of human recombinant Mr 24,000 bFGF. J Cell Physiol 1994, 161, 149-159.
3. 3. Montesano R, Vassalli J-D, Baird A, Guillemin R, Orci L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA 1986, 83, 7297-7301.
4. 4. Mignatti P, Tauboi R, Robbins E, Rifkin DB. In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor. J Cell Biol 1989, 108, 671-682.
5. 5. Klein S, Giancotti FG, Presta M, Albelda SM, Buck CA, Rifkin DB. Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells. Mol Biol Cell 1993, 4, 973-982.
6. 6. Pepper MS, Meda P. Basic fibroblast growth factor increases junctional communication and connexin 43 expression in microvascular endothelial cells. J Cell Physiol 1992, 153, 196-205.
7. 7. Mignatti P, Mazzieri R, Rifkin DB. Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor. J Cell Biol 1991, 113, 1193-1201.
8. 8. Broadly KN, Aquino AM, Woodward SC, et al. Monospecific antibodies implicate basic fibroblast growth factor in normal wound repair. Lab Invest 1989, 61, 571-575.
9. 9. Ribatti D, Urbinati C, Nico B, Rusnati M, Roncali L, Presta M. Endogenous basic fibroblast growth factor in the vascularization of the chick embryo chorioallantoic membrane. Dev Biol 1995, 170, 39-49.
10. 10. Presta M, Moscatelli D, Joseph-Silverstein J, Rifkin DB. Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration. Mol Cell Biol 1986, 6, 4060-4066.
11. 11. Moscatelli D, Presta M, Joseph-Silverstein J, Rifkin DB. Both normal and tumor cells produce basic fibroblast growth factor. J Cell Physiol 1986, 129, 273-276.
12. 12. Okumura N, Takimoto K, Okada M, Nakagawa H. C6 glioma cells produce basic fibroblast growth factor that can stimulate their own proliferation. J Biochem 1989, 106, 904-909.
13. 13. Nakamoto T, Chang C, Li A, Chodak GW. Basic fibroblast growth factor in human prostate cancer cells. Cancer Res 1992, 52, 571-577.
14. 14. Schulze-Osthoff K, Risau W, Vollmer E, Sorg C. In situ detection of basic fibroblast growth factor by highly specific antibodies. Am J Pathol 1990, 137, 85-92.
15. 15. Zagzag D, Miller DC, Sato Y, Rifkin DB, Burstein DE. Immunohistochemical localization of basic fibroblast growth factor in astrocytomas. Cancer Res 1990, 50, 7393-7398.
16. 16. Ohtani H, Nakamura S, Watanabe Y, Mizoi T, Saku T, Nagura H. Immunocytochemical localization of basic fibroblast growth factor in carcinomas and inflammatory lesions of the human digestive tract. Lab Invest, 68, 520-527.
17. 17. Takahashi JA, Mon H, Fukumoto M, et al. Gene expression of fibroblast growth factors in human gliomas and meningiomas: demonstration of a cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues. Proc Natl Acad Sci USA 1990, 87, 5710-5714.
18. 18. Abraham JA, Mergia A, Whang JL, et al. Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. Science 1986, 233, 545-548.
19. 19. Mignatti P, Morimoto T, Rifkin DB. Basic fibroblast growth factor released by single, isolated cells stimulates their migration in an autocrine manner. Proc Natl Acad Sci USA 1991, 88, 11007-11011.
20. 20. Mignatti P, Morimoto T, Rifkin DB. Basic fibroblast growth factor, a protein devoid of secretory signal sequence, is released by cells via a pathway independent of the endoplasmic reticulum-Golgi complex. J Cell Physiol 1992, 151, 81-93.
21. 21. Vlodavsky I, Bar-Shavit R, Ishai-Michaeli R, Bashkin P, Fuks Z. Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism? Trends Biochem Sci 1991, 16, 268-271.
22. 22. Kandell J, Bossy-Wetzei E, Radvanyi F, Klagsbrun M, Folkman J, Hanahan D. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 1991, 66, 1095-1104.
23. 23. Gross JL, Herblin WF, Dusak BA, et al. Effects of modulation of basic fibroblast growth factor on tumor growth in vivo. J Natl Cancer Inst 1993, 85, 121-131.
24. 24. Hori A, Sasada R, Matsutani E, et al. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 1991, 51, 6180-6184.
25. 25. Schweigerer L, Neufeld G, Friedman J, Abraham JA, Fiddes JC, Gospodarowicz D. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Nature 1987, 325, 257-259.
26. 26. Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RA. Cellular markets that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994, 93, 2357-2364.
27. 27. Ensoli B, Gendelman R, Markham P, et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 1994, 371, 674-680.
28. 28. Rusnati M, Casarotti G, Pecorelli S, Ragnotti G, Presta M. Basic fibroblast growth factor in ovulatory cycle and postmenopausal human endometrium. Growth Factors 1990, 3, 299-307.
29. 29. Milner PG, Li Y-S, Hoffman RM. A novel 17 kD heparin-binding growth factor (HBGF-8) in bovine uterus: purification and N-terminal amino acid sequence. Biochem Biophys Res Commun 1989, 165, 1096-1103.
30. 30. Rusnati M, Casarotti G, Pecorelli S, Ragnotti G, Presta M. Estro-progestinic replacement therapy modulates the levels of basic fibroblast growth factor (bFGF) in postmenopausal endometrium. Gynecol Oncol 1993, 48, 88-93.
31. 31. Gold LI, Saxena B, Mittal KR, et al. Increased expression of transforming growth factor β isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: evidence for paracrine and autocrine action. Cancer Res 1994, 54, 2347-2358.
32. 32. Presta M. Sex hormones modulate the synthesis of basic fibroblast growth factor in human endometrial adenocarcinoma cells: implications for the neovascularization of normal and neoplastic endometrium. J Cell Physiol 1988, 137, 593-597.
33. 33. Coltrini D, Gualandris A, Nelli EE, et al. Growth advantage and vascularization induced by basic fibroblast growth factor overexpression in endometrial HEC-1-B cells: an export-dependent mechanism of action. Cancer Res 1995, 55, 4729-4738.
34. 34. Hori A, Sasada R, Matsutani E, et al. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 1991, 51, 6180-6184.
35. 35. McLeskey SW, Kurebayashi J, Honig SF, et al. Fibroblast growth factor 4 transfection of MCF-7 cells produces cell lines that are tumorigenic and metastatic in ovarietomized or tamoxifen-treated athymic nude mice. Cancer Res 1993, 53, 2168-2177.
36. 36. Zhang H-T, Craft P, Scott PAE, et al. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst 1995, 87, 213-219.
37. 37. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994, 86, 356-361.
38. 38. Li VW, Folkerth RD, Watanabe H, et al. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumors. Lancet 1994, 344, 82-86.
39. 39. Peverali FA, Mandriota SJ, Ciana P, et al. Tumor cells secrete an angiogenic factor that stimulates basic fibroblast growth factor and urokinase expression in vascular endothelial cells. J Cell Physiol 1994, 161, 1-14.
40. 40. Weich H, Iberg N, Klagsbrun M, Folkman J. Transcriptional regulation of basic fibroblast growth factor gene expression in capillary endothelial cells. J Cell Biochem 1991, 47, 158-194.
41. 41. Cozzolino F, Torcia M, Lucibello M, et al. Cytokine-mediated control of endothelial cell growth: interferon-α and interleukin-2 synergistically enhance basic fibroblast growth factor synthesis and induce release promoting cell growth in vitro and in vivo. J Clin Invest 1993, 91, 2054-2512.
42. 42. Gualandris A, Rusnati M, Belleri M, et al. Basic fibroblast growth factor overexpression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases. Cell Growth Differ 1996, 7, 147-160.
43. 43. Gualandris A, Rusnati M, Belleri M, et al. Angiogenic phenotype induced by basic fibroblast growth factor transfection in brain microvascular endothelial cells: an in vitro autocrine model of angiogenesis in brain tumors. Int J Oncol 1996, 8, 567-573.
44. 44. Thomas KA. Vascular endothelia growth factor, a potent and selective angiogenic agent. J Biol Chem 1996, 271, 603-606.
45. 45. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 1991, 88, 9267-9271.
46. 46. Maglione D, Guerriero V, Viglietto G, et al. Two alternative mRNAs coding for the angiogenic factor, placental growth factor (P1GF), are transcribed from a single gene of chromosome 14. Oncogene 1993, 8, 925-931.
47. 47. Hauser S, Weich HA. A heparin-binding form of placenta growth factor (P1GF-2) is expressed in human umbilical vein endothelial cells and placenta. Growth Factors 1993, 9, 259-268.
48. 48. Park JE, Chen HH, Winer J, Houck KA, Ferrara N. Placenta growth factor: potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not Flk-1/KDR. J Biol Chem 1994, 269, 25646-25654.
49. 49. Sawano A, Takahashi T, Yamaguchi S, Aonuma M, Shibuya M. Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placental growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ 1996, 7, 213-221.
50. 50. Birkenhagen R, Schneppe B, Rocki W, Wilting J, Weich H, McCarty JEG. Synthesis and physiological activity of heterodimer comprising different splice forms of vascular endothelial growth factor and placental derived growth factor. Biochem J 1996, 316, 703-707.
51. 51. Salvo J, Bayne ML, Conn G, et al. Purification and characterization of a naturally occurring vascular endothelial growth factor - placenta growth factor heterodimer. J Biol Chem 1995, 270, 7717-7723.
52. 52. Cao Y, Chen H, Zhou L, et al. Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression and high affinity binding to Flk-1/KDR1. J Biol Chem 1996, 271, 3154-3162.
53. 53. Terman BI, Khandke L, Dougher-Vermazan M, et al. VEGF receptor subtypes KDR and FLT1 show different sensitivities to heparin and placenta growth factor. Growth Factors 1994, 11, 187-195.
54. 54. Viglietto G, Romano A, Maglione D, et al. Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta growth factor. Oncogene, in press.
55. 55. Takahashi Y, Kitadai Y, Bucana C, Cleary K, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995, 55, 3964-3968.
56. 56. Takahashi A, Sasaki H, Kim SJ. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 1994, 54, 4233-4237.
57. 57. Hatva E, Kaipainen A, Mentula P, et al. Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. Am J Pathol 1995, 146, 368-378.
58. 58. Viglietto G, Maglione D, Rambaldi M, et al. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (P1GF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 1995, 11, 1569-1579.
59. 59. Sato K, Yamazaki K, Shizume K, et al. Stimulation by thyroid-stimulating hormone and Grave's immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo. J Clin Invest 1995, 96, 1295-1302.
60. 60. Di Palma T, Tucci M, Russo G, et al. The placental growth factor gene of the mouse. Mammalian Genome 1996, 7, 6-12.
61. 61. Claffey KP, Wilkinson WO, Spiegelman BM. Vascular endothelial growth factor: regulation by cell differentiation and activated second messenger pathways. J Biol Chem 1992, 267, 16317-16322.
62. 62. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359, 843-845.
63. 63. Comoglio P. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells. In Goldberg ID, Rosen EM, eds. Hepatocyte Growth Factor-Scatter Factor (HGF-SF) and the c-Met Receptor. Basel, Switzerland, Birkhauser-Verlag, 1993, 131-165.
64. 64. Bussolino F, Di Renzo MF, Ziche M, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992, 119, 629-641.
65. 65. Silvagno F, Follenzi A, Arese M, et al. In vivo activation of Met tyrosine kinase by heterodimeric HGF molecule promotes angiogenesis. Arterioscler Thromb Vasc Biol 1995, 15, 1857-1865.
66. 66. Rubin JS, Chan AM, Bottaro DP, et al. A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor. Proc Natl Acad Sci USA 1991, 88, 415-419.
67. 67. Morimoto A, Okamura K, Hamanaka R, et al. Hepatocyte growth factor modulates migration and proliferation of human microvascular endothelial cells in culture. Biochem Biophys Res Commun 1991, 179, 1042-1049.
68. 68. Taipale J, Keski-Oja. Hepatocyte growth factor releases epithelial and endothelial cells from growth arrest induced by transforming growth factor-beta 1. J Biol Chem 1996, 271, 4342-4348.
69. 69. Grant DS, Kleinman HK, Goldberg ID, et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 1993, 90, 1937-1941.
70. 70. Okigaki M, Komada M, Uehara Y, Miyazawa K, Kitamura N. Functional characterization of human hepatocyte growth factor mutants obtained by deletion of structural domains. Biochemistry 1992, 31, 9555-9561.
71. 71. Lokker NA, Mark MR, Luis EA, et al. Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J 1992, 11, 2503-2510.
72. 72. Hayashi S, Morishita R, Higaki J, et al. Autocrine-paracrine effects of overexpression of hepatocyte growth factor gene on growth of endothelial cells. Biochem Biophys Res Commun 1996, 220, 539-545.
73. 73. Nakamura Y, Morishita R, Higaki J, et al. Expression of local hepatocyte growth factor system in vascular tissues. Biochem Biophys Res Commun 1995, 215, 483-488.
74. 74. Maher JJ. Cell-specific expression of hepatocyte growth factor in liver. Upregulation in sinusoidal endothelial cells after carbon tetrachloride. J Clin Invest 1993, 91, 2244-2252.
75. 75. Naidu YM, Rosen ME, Zitnick R, et al. Role of scatter factor in the pathogenesis of AIDS-related Kaposi's sarcoma. Proc Natl Acad Sci USA 1994, 91, 5281-5285.
76. 76. Maier JA, Mariotti M, Albini A, et al. Over-expression of hepatocyte growth factor in human Kaposi's sarcoma. Int J Cancer 1996, 65, 168-172.
77. 77. Vogel J, Hinrichs SH, Reynolds RK, Luciw PA, Jay G. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature 1988, 335, 606-611.
78. 78. Corallini A, Altavilla G, Pozzi L, et al. Systemic expression of HIV1 tat gene in transgenic mice induces endothelial proliferation and tumors of different histotypes. Cancer Res 1993, 53, 5569-5575.
79. 79. Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 1990, 345, 84-86.
80. 80. Albini A, Barillari G, Benelli R, Gallo RC, Ensoli B. Angiogenic properties of human immunodeficiency virus type 1 Tat protein. Proc Natl Acad Sci USA 1995, 92, 4838-4842.
81. 81. Corallini A, Campioni D, Rossi C, et al. Promotion of tumor metastases and induction of angiogenesis by native HIV-1 Tat protein from BK virus/tat transgenic mice. AIDS, in press.
82. 82. Benelli R, Masiello L, Paglialunga G, et al. IFNα inhibits Tat-induced angiogenesis. Colloques de l'Inserm, in press.
83. 83. Barillari G, Bonaguro L, Fiorelli V, et al. Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression. Implications for AIDS-Kaposi's sarcoma pathogenesis. J Immunol 1992, 149, 3727-3734.
84. 84. Brake D, Debouck C, Biesecker G. Identification of an Arg-Gly-Asp (RGD) cell adhesion site in human immunodeficiency virus type 1 transactivation protein, tat. J Cell Biol 1990, 111, 1275-1281.
85. 85. Ruoslahti E, Pierschbacher PM. New perspectives in cell adhesion: RGD and integrins. Science 1987, 238, 491-497.
86. 86. Barillari G, Gendelman R, Gallo RC, Ensoli B. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci USA 1993, 90, 7941-7945.
87. 87. Albini A, Fontanini G, Masiello L, et al. Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV1-tat product: inhibition of KS-lesions by TIMP-2. AIDS 1994, 8, 1237-1244.
88. 88. Albini A, Benelli R, Presta M, et al. HIV-tat protein is a heparin-binding angiogenic growth factor. Oncogene 1996, 12, 289-297.
89. 89. Yayon A, Klagsbrun M, Esko D, Lader P, Ornitz DM. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991, 64, 841-848.
90. 90. Snyder F. Platelet-activating factor and related acetylated lipids as potent biological acting cellular mediators. Am J Physiol 1990, 259, 697-705.
91. 91. Korth R, Hirafuji M, Lalau Keraly C, Delautier D, Bidault J, Benveniste J. Interaction of the antagonist WEB 2086 and its hetrazepine analogue with human platelets and endothelial cells. Biochem Pharmacol 1989, 44, 223-231.
92. 92. Bussolino F, Camussi G, Aglietta M, et al. Human endothelial cells are a target for platelet-activating factor. I. Platelet-activating factor induces changes in cytoskeleton structure and promotes albumin diffusion across endothelial monolayer. J Immunol 1987, 13, 2439-2446.
93. 93. Camussi G, Montrucchio G, Lupia E, et al. Platelet-activating factor directly stimulates in vitro migration of endothelial cells and promotes in vivo angiogenesis by a heparin-dependent mechanism. J Immunol 1995, 154, 6492-6501.
94. 94. Bussolino F, Silvagno F, Garbarino G, et al. Human endothelial cells are targets for platelet-activating factor (PAF). Activation of α and β protein kinase C isozymes in endothelial cells stimulated by PAF. J Biol Chem 1994, 269, 2877-2886.
95. FAK) in human endothelial cells. Oncogene, in press.
96. 96. Nakamura M, Honda ZI, Izumi T. Molecular cloning and expression of platelet-activating factor receptor from human leukocytes. J Biol Chem 1991, 266, 20400-20407.
97. 97. Montrucchio G, Lupia E, Battaglia E, et al. Tumor necrosis factor α-induced angiogenesis depends on in situ platelet-activating factor biosynthesis. J Exp Med 1994, 180, 377-382.
98. 98. Bussolino F, Arese M, Montrucchio G, et al. Platelet activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis. J Clin Invest 1995, 96, 940-952.
99. 99. Moncada S, Palmer RMJ, Higgs A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991, 43, 109-142.
100. 100. Ziche M, Morbidelli L, Masini E, Granger HJ, Geppetti G, Ledda F. Nitric oxide promotes DNA synthesis and cyclic GMP formation in endothelial cells from postcapillary venules. Biochem Biophys Res Commun 1993, 192, 1198-1203.
101. 101. Ziche M, Morbidelli L, Masini E, et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 1994, 94, 2036-2044.
102. 102. Leibovicz JS, Polverini PJ, Fong TW, Harlow LA, Kock AE. Production of angiogenic activity by human monocytes requires an L-arginine/nitric oxide-synthase-dependent effector mechanism. Proc Natl Acad Sci USA 1994, 91, 4190-4194.
103. 103. Brzozowski T, Kounturek SJ, Drozdowicz D, Dembinski A, Stachura J. Healing of chronic gastric ulcerations by L-arginine. Digestion 1995, 56, 463-471.
104. 104. Ghigo D, Arese M, Todde R, et al. Middle T antigen-transformed endothelial cells exhibit an increased activity of nitric oxide synthase. J Exp Med 1995, 181, 9-19.
105. 105. Pipili-Synetos E, Sakkoula E, Haralabopoulos G, Andiopuolou P, Peristeris P, Maragoudakis ME. Evidence that nitric oxide is an endogenous antiangiogenic mediator. Br J Pharmacol 1994, 111, 894-902.
106. 106. Andrade SP, Bakhle YS, Hart I, Piper PJ. Effect of tumour cells on angiogenesis and vasoconstrictor response in sponge implants in mice. Br J Cancer 1992, 66, 821-826.
107. 107. Jenkins DC, Charles IG, Thomsen LL, et al. Role of nitric oxide in tumor growth. Proc Natl Acad Sci USA 1995, 92, 4392-4396.
108. 108. Kennovin GD, Hirst DG, Stratford MRL, Flitney FW. Inducible nitric oxide synthase is expressed in tumour associated vasculature; inhibition retards tumour growth in vivo. Immunol and Inflamm 1996, 473-479.
109. 109. Zhang H-T, Craft P, Scott PAE, et al. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst 1995, 87, 213-217.
110. 110. Morbidelli L, Chang C-H, Douglas JG, Granger HJ, Ledda F, Ziche M. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am J Physiol 1996, 270, Heart Circ Physiol, 39, H411-H415.
111. 110. Morbidelli L, Chang C-H, Douglas JG, Granger HJ, Ledda F, Ziche M. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am J Physiol 1996, 270, Heart Circ Physiol, 39, H411-H415.